Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216418 | 0.93 | TDP1 (0.46) | KMT2ATDP1HTTL3MBTL1POLB | |
| SCHEMBL295163 | 0.82 | ALDH1A1 (0.50) | KMT2ATDP1HTTL3MBTL1 | |
| SCHEMBL2696686 | 0.81 | ALDH1A1 (0.48) | KMT2ATDP1HTTL3MBTL1CYP1A2 | |
| SCHEMBL3985824 | 0.79 | KMT2A (0.51) | KMT2ATDP1HTTLMNAL3MBTL1 | |
| SCHEMBL13302447 | 0.77 | HTT (0.56) | KMT2ATDP1HTTLMNAL3MBTL1 | |
| SCHEMBL24998780 | 0.76 | KMT2A (0.51) | KMT2ATDP1HTTLMNAL3MBTL1 | |
| SCHEMBL27270658 | 0.76 | ALDH1A1 (0.52) | KMT2ATDP1HTTLMNAL3MBTL1 | |
| SCHEMBL4212544 | 0.75 | ALDH1A1 (0.37) | KMT2ATDP1LMNA | |
| SCHEMBL16938545 | 0.73 | TDP1 (0.46) | KMT2ATDP1HTTL3MBTL1POLB | |
| SCHEMBL14123973 | 0.73 | L3MBTL1 (0.54) | KMT2ATDP1HTTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051388-A1 | Novel Compounds That Inhibit Factor Xa Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1773855-A1 | NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008141-A1 | NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051388-A1 | Novel Compounds That Inhibit Factor Xa Activity | SERPINC1, TFPI, F11 | KMT2A 4548/4885TDP1 2550/4885HTT 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.